{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:43:35Z","timestamp":1789249415638,"version":"build-2803163510"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T00:00:00Z","timestamp":1453680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0147391","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T19:17:59Z","timestamp":1453749479000},"page":"e0147391","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":71,"title":["The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic \u03b2-Cell Mass and Glucose Homeostasis in Type 1 Diabetes"],"prefix":"10.1371","volume":"11","author":[{"given":"Sam Tsz Wai","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Yu Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mayoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po Sing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,1,25]]},"reference":[{"issue":"3","key":"ref1","first-page":"92","article-title":"Type 1 diabetes mellitus and pregnancy","volume":"3","author":"R Vargas","year":"2010","journal-title":"Rev Obstet Gynecol"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1753-0407.2010.00102.x","article-title":"Prediction and prevention of Type 1 diabetes mellitus","volume":"3","author":"L Zhang","year":"2011","journal-title":"J Diabetes"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2337\/diaclin.26.4.170","article-title":"Hypoglycemia","volume":"26","author":"MJ Fowler","year":"2008","journal-title":"Clinical Diabetes"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"V Vallon","year":"2015","journal-title":"Annu Rev Med"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"V Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"H Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","article-title":"Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney","volume":"74","author":"V Vallon","year":"2012","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"MJ Jurczak","year":"2011","journal-title":"Diabetes"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"JR Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/13543784.2013.774372","article-title":"Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus","volume":"22","author":"WN Washburn","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2174\/156652412802480970","article-title":"Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db\/db mice","volume":"12","author":"L Chen","year":"2012","journal-title":"Curr Mol Med"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1463-1326.2011.01518.x","article-title":"Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats","volume":"14","author":"L Thomas","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"V Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","volume":"14","author":"G Luippold","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/13543784.2014.909407","article-title":"Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes","volume":"23","author":"EM Lamos","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"RR Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrendo.2014.2","article-title":"Immune modulation in humans: implications for type 1 diabetes mellitus","volume":"10","author":"BO Roep","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"ref18","first-page":"451","article-title":"Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management of Type-2 Diabetes: A Drug Class Overview","volume":"40","author":"JF Mosley 2nd","year":"2015","journal-title":"P T"},{"key":"ref19","first-page":"1","article-title":"Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus","author":"N Rosenthal","year":"2015","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yang T, Lu M, Ma L, Zhou Y, Cui Y. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. 2015.","DOI":"10.1007\/s00228-015-1923-y"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects","volume":"28","author":"CE Mogensen","year":"1971","journal-title":"Scand J Clin Lab Invest"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"BA Perkins","year":"2014","journal-title":"Diabetes Care"},{"issue":"1 Suppl","key":"ref23","first-page":"S11","article-title":"Understanding the Kidneys' Role in Blood Glucose","volume":"18","author":"CL Triplitt","year":"2012","journal-title":"Am J Manag Care"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2337\/diacare.24.2.382","article-title":"Renal Gluconeogenesis: Its importance in human glucose homeostasis","volume":"24","author":"JE Gerich","year":"2001","journal-title":"Diabetes Care"},{"issue":"41","key":"ref25","doi-asserted-by":"crossref","first-page":"42351","DOI":"10.1074\/jbc.R400019200","article-title":"Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes","volume":"279","author":"RP Robertson","year":"2004","journal-title":"J Biol Chem"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1172\/JCI116596","article-title":"Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein","volume":"92","author":"LK Olson","year":"1993","journal-title":"J Clin Invest"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tips.2008.02.001","article-title":"Preservation of beta-cell function by targeting beta-cell mass","volume":"29","author":"EJ de Koning","year":"2008","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"J Chen","year":"2010","journal-title":"Diabetes Ther"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","article-title":"Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences","volume":"302","author":"I Sabolic","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"C Bonner","year":"2015","journal-title":"Nature Medicine"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diab.37.7.920","article-title":"Prospective study of predictors of beta-cell survival in type I diabetes","volume":"37","author":"A Schiffrin","year":"1988","journal-title":"Diabetes"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0147391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:26:53Z","timestamp":1567556813000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0147391"}},"subtitle":[],"editor":[{"given":"Angel","family":"Nadal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,25]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0147391","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,25]]}}}